Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2008

01-04-2008 | Gastrointestinal Oncology

Advances in Laparoscopic Gastrectomy Expand Clinical Use

Authors: E. Hanisch, PhD, D. Ziogas, MD, D. Roukos, MD, C. Hottenrott, MD

Published in: Annals of Surgical Oncology | Issue 4/2008

Login to get access

Excerpt

Although laparoscopic gastrectomy is unlikely to improving survival or cure rates for gastric cancer patients, strong evidence indicates its superiority over open gastrectomy in improving quality of life (QOL). Another important field of laparoscopic approach is its clinical use in the risk-reducing prophylactic gastrectomy. But particularly for these healthy individuals, who are carriers of mutations in CDH1, the safety and efficacy is precondition for the clinical application of the laparoscopic approach.1 …
Literature
1.
Ziogas D, Baltogiannis, Fatouros M, et al. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg (in press)
2.
Lee JH, Kim YW, Ryu KW. A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with d2 lymph node dissection for gastric cancer patients. Ann Surg Oncol 2007 Aug 20; [Epub ahead of print]
3.
Roukos DH, Hottenrott C, Lorenz M, et al. A critical-evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach - an analysis of early results and long-term survival. J Cancer Res Clin 1990;116:307–13CrossRef
4.
Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449–61PubMedCrossRef
5.
Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002;81:59–62PubMedCrossRef
6.
Kappas AM, Fatouros M, Roukos DH. Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004;11:727–30PubMedCrossRef
7.
8.
Wu CW, Hsiung SA, Lo, et al. Nodal dissection for patients with gastric cancer: a randomized trial. Lancet Oncol 2006;7:309–15
9.
10.
Roukos DH, Hottenrott C, Encke A, et al. Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 1994;3:115–25PubMedCrossRef
11.
Gervasoni JE, Sbayi S, Cady B. Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol 2007 (in press) DOI: 10.​1245/​s10434-007-9360-5
12.
Roukos DH, Kappas AM. Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2005;2:98–107PubMedCrossRef
13.
Roukos DH, Lorenz M, Karakostas K, et al. Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 2001;84:1602–9PubMedCrossRef
14.
Roukos DH. Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 1998;80:16–24PubMed
15.
Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000;7:253–5PubMedCrossRef
16.
Roukos DH. Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 1999;6:46–56PubMedCrossRef
17.
Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 1998;123:573–8PubMedCrossRef
18.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–30PubMedCrossRef
19.
Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 2002;9:220–1PubMedCrossRef
20.
Shehzad K, Mohiuddin K, Nizami S, et al. Current status of minimal access surgery for gastric cancer. Surg Oncol 2007;16:85–98. Epub 2007 Jun 7PubMedCrossRef
21.
Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 2007;245:873–9PubMedCrossRef
22.
Chung DC, Yoon SS, Lauwers GY, et al. Case records of the Massachusetts General Hospital. Case 22–2007. A woman with a family history of gastric and breast cancer. N Engl J Med 2007;357:283–91PubMedCrossRef
23.
Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 2007;6:308–12PubMedCrossRef
24.
Kim JJ, Song KY, Chin HM, et al. Totally laparoscopic gastrectomy with various types of intracorporeal anastomosis using laparoscopic linear staplers: preliminary experience. Surg Endosc 2007 Jun 26; [Epub ahead of print]
25.
Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 2007;4:578–90PubMedCrossRef
26.
Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 2002;9:607–9PubMed
27.
Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 2002;9:941–3PubMed
28.
Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of hereditary breast ovarian cancer. Ann Surg Oncol 2007 Oct 17; [Epub ahead of print] (DOI:10.​1245/​s10434-007-9612-4)
29.
Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 2004;11:1030–4PubMedCrossRef
30.
Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:1555–6PubMedCrossRef
31.
Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 2003;10:718–21PubMedCrossRef
32.
Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5:737–45
Metadata
Title
Advances in Laparoscopic Gastrectomy Expand Clinical Use
Authors
E. Hanisch, PhD
D. Ziogas, MD
D. Roukos, MD
C. Hottenrott, MD
Publication date
01-04-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9721-0

Other articles of this Issue 4/2008

Annals of Surgical Oncology 4/2008 Go to the issue

Laboratory Research

Enhanced Tumour Growth and Impaired Cellular Antitumoural Defence in Hepatic Colorectal Carcinoma Metastasis in Rats after Laparoscopy Compared to Open Surgery

Breast Oncology

Axilla Scoring Systems Predicting Risk of Non-sentinel-node Metastasis in Breast Cancer Patients with a Positive Sentinel Node

Gastrointestinal Oncology

More Controversy than Ever – Challenges and Promises Towards Personalized Treatment of Gastric Cancer

Other

Ongoing Studies with GM.CD40L Bystander-Based Vaccines

Gastrointestinal Oncology

Color Doppler Imaging Predicts Portal Invasion by Pancreatic Adenocarcinoma

Hepatic and Pancreatic Tumors

Treatment before Liver Transplantation for HCC